United States - English - NLM (National Library of Medicine)

gsk vaccines gmbh - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

United States - English - NLM (National Library of Medicine)

a-s medication solutions - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - rabies virus strain pasteur riv inactivated - suspension for injection - unknown - rabies virus vaccine - canine, feline - immunological - inactivated vaccine

Ireland - English - HPRA (Health Products Regulatory Authority)

merial animal health limited - rabies virus glycoproteins g52 rabies virus strain - suspension for injection - per cent - rabies virus vaccine - bovine, canine, equine - food, feline, mustelids, ovine - immunological - inactivated vaccine

Philippines - English - FDA (Food And Drug Administration)

msd animal health (phils.), inc.; distributor: msd animal health (phils.), inc. - inactivated rabies virus vaccine (vet.) - suspension for injection (sc/im) - formulation: each 1 ml (dose) contains: rabies virus (pasteur riv strain).............. > 2i.u. iu-international units

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 virus - immunologicals - cats - active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.onset of immunity: 4 weeks after the primary vaccination course.duration of immunity after primary vaccination: 1 year.duration of immunity after revaccination: 3 years.

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - inactivated rabies virus, strain vnukovo-32 - suspension for injection - minimum 2.0 international unit(s) - rabies virus - cats, cattle, dogs, ferrets, goats, horses, pigs, sheep - immunological - inactivated vaccine

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabies immunoglobulin, quantity: 150 iu/ml - injection - excipient ingredients: glycine; sodium chloride; water for injections - imogam rabies pasteurized is indicated in subjects who are thought to have been exposed to rabies virus, especially cases of major exposure, in accordance with w.h.o. recommendations as specified in the international product information.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 300 [iu] in 1 ml - hyperrab is a human rabies immune globulin indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies. limitations of use persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.(1-3) for unvaccinated persons, the combination of hyperrab and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.(1-3) beyond 7 days (after the first vaccine dose), hyperrab is not indicated since an antibody response to vaccine is presumed to have occurred. none. risk summary there are no data with hyperrab use in pregnant women to inform a drug-associated risk.  animal reproduction studies have not been conducted with hyperrab.  it is not known whether hyperrab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  hyperrab should be given to a pregna

Philippines - English - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation - live attenuated canine distemper virus (cdv) , canine adenovirus type 1 (cav-1) , canine adenovirus type 2 (cav-2) , canine parvovirus (cpv) , canine parainfluenza virus (cpiv) , inactivated leptospira interrogans var. icterohaemorrhagiae , leptospira interrogans var. grippotyphosa , leptospira interrogans var. sejroe , rabies virus (rv) vaccine (vet.) - freeze-dried powder for injection (sc) - formulation: each ml (dose) contains: live attenuated canine distemper virus (cdv)...... >10^2.7-4.5 eid50 canine adenovirus type 1 (cav-1). .................. >10^3.5-7.5 tcid 50 canine adenovirus type 2 (cav-2)................... >10^3.5-7.5 tcid50 canine parvovirus (cpv)............. >10^2.1-3.6 hau canine parainfluenza virus (cpiv)..................... >10^3-6 ccid 50 inactivated leptospira interrogans var. icterohaemorrhagiae....... >32 vnab50 leptospira interrogans var. grippotyphosa.......>32 vnab50 leptospira interrogans var. sejroe............... >32 vnab 50 rabies virus (rv)................ >2 iu eid - egg infectious dose tcid-tissue culture infectious dose ccid-cell culture infectious dose hau - haemagglutination unit iu - international unit